More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8%...

|By:, SA News Editor

More on ImmunoGen (IMGN): The stock's moving about quite a bit, but currently +3.8% following FDA approval of Kadcyla. The drug is being approved with a Boxed Warning alerting users and prescribers of heart and liver toxicity as well as severe life-threatening birth defects.